TKT Regains European Rights to Dynepo
French drug maker Aventis has returned rights to Transkaryotic Therapies for the anemia treatment Dynepo, which the companies have been unable to market because of a long-running patent dispute with biotech...To view the full article, register now.
Already a subscriber? Click here to view full article